Natasha Leighl

Natasha B Leighl, MD MMSc FRCPC
Medical Oncologist, Princess Margaret Hospital/University Health Network,
Assistant Professor, Department of Medicine, University of Toronto

Dr Natasha Leighl is a medical oncologist at the Princess Margaret Hospital and Assistant Professor in the Department of Medicine at the University of Toronto.

After receiving her MD from the University of Toronto, Canada, Dr. Leighl completed residencies in internal medicine at the University of Calgary and in medical oncology at the University of Toronto. She subsequently completed a Fellowship in Thoracic Oncology with Dr. Frances Shepherd at the Princess Margaret Hospital in Canada, a Fellowship in Clinical Oncology with Prof. Martin Tattersall at the University of Sydney in Australia, and received her Master of Medical Science in Clinical Epidemiology at the University of Newcastle, Australia.

Dr Leighl’s main interests lie in the management of lung and breast cancer, and in patient-physician communication and treatment decision-making. She is involved in clinical studies of novel agents for the treatment of lung and breast cancer, and has been a member of the Lung Disease Site Group Executive in the National Cancer Institute of Canada Clinical Trials Group. She has received a prestigious American Society of Clinical Oncology (ASCO) Career Development Award, ASCO Young Investigator Award and International Association for the Study of Lung Cancer Young Investigator Award for her work in developing treatment decisions aids for patients with advanced lung, breast and colorectal cancer. Dr Leighl has served on committees including the Royal College of Physicians and Surgeons of Canada Credentials Committee, the University of Toronto Undergraduate Medical Education Committee, and is currently a member of the University Health Network Research Ethics Board, National Cancer Institute of Canada Grant Review Panel (I), and Canadian Breast Cancer Foundation Grant Review Panel (Ontario Chapter). She has recently been appointed Co-Chair of the Working Group on Economic Analysis for the National Cancer Institute of Canada Clinical Trials Group.